ATAI
Price
$4.52
Change
-$0.07 (-1.53%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
968.81M
75 days until earnings call
CYBN
Price
$6.01
Change
-$0.23 (-3.69%)
Updated
Sep 3 closing price
Capitalization
149.33M
Interact to see
Advertisement

ATAI vs CYBN

Header iconATAI vs CYBN Comparison
Open Charts ATAI vs CYBNBanner chart's image
ATAI Life Sciences
Price$4.52
Change-$0.07 (-1.53%)
Volume$31.81K
Capitalization968.81M
Cybin
Price$6.01
Change-$0.23 (-3.69%)
Volume$1.33M
Capitalization149.33M
ATAI vs CYBN Comparison Chart in %
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. CYBN commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Buy and CYBN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ATAI: $4.59 vs. CYBN: $6.24)
Brand notoriety: ATAI and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 46% vs. CYBN: 383%
Market capitalization -- ATAI: $968.81M vs. CYBN: $149.33M
ATAI [@Biotechnology] is valued at $968.81M. CYBN’s [@Biotechnology] market capitalization is $149.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, ATAI is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 3 TA indicator(s) are bullish while CYBN’s TA Score has 3 bullish TA indicator(s).

  • ATAI’s TA Score: 3 bullish, 5 bearish.
  • CYBN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than CYBN.

Price Growth

ATAI (@Biotechnology) experienced а -4.97% price change this week, while CYBN (@Biotechnology) price change was -16.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

ATAI is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($969M) has a higher market cap than CYBN($149M). ATAI YTD gains are higher at: 245.113 vs. CYBN (-29.252). ATAI has higher annual earnings (EBITDA): -115.96M vs. CYBN (-152.51M). CYBN has more cash in the bank: 119M vs. ATAI (95.9M). ATAI has less debt than CYBN: ATAI (9.22M) vs CYBN (44.5M). ATAI has higher revenues than CYBN: ATAI (2.31M) vs CYBN (0).
ATAICYBNATAI / CYBN
Capitalization969M149M650%
EBITDA-115.96M-152.51M76%
Gain YTD245.113-29.252-838%
P/E RatioN/AN/A-
Revenue2.31M0-
Total Cash95.9M119M81%
Total Debt9.22M44.5M21%
FUNDAMENTALS RATINGS
ATAI vs CYBN: Fundamental Ratings
ATAI
CYBN
OUTLOOK RATING
1..100
172
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
8496
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3562
P/E GROWTH RATING
1..100
13100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYBN's Valuation (18) in the null industry is somewhat better than the same rating for ATAI (73) in the Miscellaneous Commercial Services industry. This means that CYBN’s stock grew somewhat faster than ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (84) in the Miscellaneous Commercial Services industry is in the same range as CYBN (96) in the null industry. This means that ATAI’s stock grew similarly to CYBN’s over the last 12 months.

ATAI's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as CYBN (98) in the null industry. This means that ATAI’s stock grew similarly to CYBN’s over the last 12 months.

ATAI's Price Growth Rating (35) in the Miscellaneous Commercial Services industry is in the same range as CYBN (62) in the null industry. This means that ATAI’s stock grew similarly to CYBN’s over the last 12 months.

ATAI's P/E Growth Rating (13) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CYBN (100) in the null industry. This means that ATAI’s stock grew significantly faster than CYBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAICYBN
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 20 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JMPLF26.00N/A
N/A
Johnson Matthey plc
PYPTF9.39N/A
N/A
Paypoint plc
TTDKY12.81-0.09
-0.70%
TDK Corp.
WSTL5.60-0.21
-3.61%
Westell Technologies, Inc.
XYLB0.24-0.01
-4.00%
XY LABS INC.

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with MNMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
+0.22%
MNMD - ATAI
51%
Loosely correlated
+2.82%
RXRX - ATAI
42%
Loosely correlated
-0.85%
CYBN - ATAI
41%
Loosely correlated
-16.58%
SYRE - ATAI
40%
Loosely correlated
+0.85%
CRSP - ATAI
39%
Loosely correlated
+1.60%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-16.58%
ATAI - CYBN
42%
Loosely correlated
+0.22%
RXRX - CYBN
36%
Loosely correlated
-0.85%
ABSI - CYBN
35%
Loosely correlated
-2.09%
ABCL - CYBN
29%
Poorly correlated
-3.11%
SPRC - CYBN
29%
Poorly correlated
-0.81%
More